| Formulary Chapter 6: Endocrine system - Full Chapter
|
|
| Chapter Links... |
 NICE Guidance on prescribing |
| NICE NG28: Type 2 diabetes in adults: management |
| DVLA guidance |
| Details... |
| 06.01.01.02 |
Intermediate- and long-acting insulins |
|
|
Insulin glargine (Semglee®)
|
First Choice
|
First line insulin for new patients initiated on insulin glargine 100units/ml and existing patients on Lantus
|
NICE NG17: Type 1 diabetes in adults: diagnosis and management
|
Insulin Detemir
|
Formulary
|
- Levemir FlexPen
- Levemir InnoLet
- Levemir Penfill
|
|
|
INSULIN GLARGINE
|
Formulary
|
- Abasaglar KwikPen
- Lantus
- Toujeo
- Toujeo DoubleStar
|
NICE NG17: Type 1 diabetes in adults: diagnosis and management
For your patients who are currently prescribed Lantus®: A guide on how to use Lantus®.
For your patients with diabetes who are currently prescribed Lantus ®: A step-by-step guide on how to use Lantus® SoloStar.
 For your patients with diabetes who are currently prescribed Toujeo® DoubleStar: A guide on how to use Toujeo® DoubleStar.
For your patients with diabetes who are currently prescribed Toujeo® SoloStar: A guide on how to use Toujeo ® SoloStar.
|
Insulin Degludec (Tresiba Flextouch ®)
(200units/ml)
|
Formulary
|
- Tresiba FlexTouch 200units/ml
 Type I Diabetes
 Type II Diabetes
|
|
|
Insulin Degludec (Tresiba®)
|
Formulary
|
- Tresiba FlexTouch 100units/ml
- Tresiba Penfill 100units/ml
|
|
|
Insulin degludec/liraglutide
|
Formulary
|
|
|
|
Isophane Insulin
|
Formulary
|
- Humulin I
- Humulin I KwikPen
- Insulatard
- Insulatard InnoLet
- Insulatard Penfill
- Insuman Basal
- Insuman Basal SoloStar
|
For your patients with diabetes who are currently prescribed Insuman® Basal: A step-by-step guide on how to use Insuman® Basal SoloStar.
|
|
|
|
|
| 06.01.01.02 |
Biphasic insulins |
|
|
Biphasic Insulin Aspart
|
Formulary
|
BRANDS
- NovoMix 30 FlexPen
- NovoMix 30 Penfill
|
|
|
Biphasic Insulin Lispro
|
Formulary
|
BRANDS
- Humalog Mix25
- Humalog Mix25 KwikPen
- Humalog Mix50
- Humalog Mix50 KwikPen
|
|
|
Biphasic Isophane Insulin
|
Formulary
|
BRANDS
- Humulin M3
- Humulin M3 KwikPen
|
|
|
Biphasic Isophane Insulin (Insuman Comb® )
|
Formulary
|
Insuman comb 25
Insuman comb 50
|
|
|
Insulin Lispro
|
Formulary
|
- Admelog
- Humalog 100units/ml
- Humalog KwikPen
- Lyumjev
- Lyumjev KwikPen
- Lyumjev Junior KwikPen
|
|
|
| 06.01.01.02 |
Intermediate Acting Insulin |
|
|
| 06.01.01.02 |
Long Acting Insulin Analogues |
|
|
| .... |
| Non Formulary Items |
Biphasic Isophane Insulin (Hypurin Porcine 30/70 Mix®)
|
Non Formulary
|
|
|
|
Biphasic Isophane Insulin (Mixtard® 30)
|
Non Formulary
|
|
|
|
Insulin degludec with insulin aspart (DegludecPlus)
|
Non Formulary
|
|
|
|
Insulin glargine 100units/ml (Abasaglar ®)
|
Non Formulary
|
Cost price is more than originator April 2023 DM+d
and DT Abasaglar (£35.28); Lantus (£34.75) |
NICE NG17: Type 1 diabetes in adults: diagnosis and management
|
Insulin Zinc suspension (Hypurin®Bovine Lente)
|
Non Formulary
|
For existing patients only
Discontinued July 2017 |
|
|
Isophane Insulin (Hypurin Bovine Isophane®)
|
Non Formulary
|
|
|
|
Isophane Insulin (Hypurin Porcine Isophane®)
|
Non Formulary
|
For existing patients only |
|
|
Isophane Insulin (Pork Insulatard®)
|
Non Formulary
|
|
|
|
Protamine Zinc Insulin (Hypurin® Bovine Protamine Zinc)
|
Non Formulary
|
For existing patients only
Discontinued July 2017 |
|
|
| |
Key |
 |
Restricted Drug |
 |
Unlicensed |
|
|
Link to adult BNF
|
|
|
Link to children's BNF
|
|
|
Link to SPCs
|
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine |
|
Cancer Drugs Fund |
|
NHS England |
|
Homecare |
|
ICB |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
| Status |
Description |
|
All Settings
Suitable for initiation, ongoing prescribing, and discontinuation in both primary and secondary care settings. They are generally familiar, frequently used therapies that can be started within their licensed indications without specialist oversight. |
|
Specialist only
Designated for initiation, ongoing prescribing, monitoring, exclusively by a specialists either in a hospital or as part of a specialist service (to note this could be in a non-hospital setting). Primary care should neither start nor continue these treatments except as part of a specialist service. A specialist could be either a medical or non-medical prescriber. |
|
Specialist advice
Prescribers in primary care should seek advice and a recommendation from a specialists prior to initiating a medicine. Once agreed with a specialist, medicines can be initiated, prescribed and monitored in primary care without a formal shared-care agreement. |
|
Specialist initiation
Medicines in this category require a specialist to start therapy, titrate dosage, and assess initial efficacy or tolerability. Once stabilised, prescribing responsibility may transfer to primary care without the need for a formal shared-care agreement. |
|
Shared care agreement
Prescribing responsibility can be shared across health settings and between specialists and GPs only when formal shared care arrangement has been made. For example, there may be extensive and complex monitoring requirements or significant safety concerns (note would need a national policy on this to define the criteria for requiring a formal SCA), this will be produced once nationally. |
|
Do not prescribe
Not approved for routine prescribing in primary or secondary care. For example, because they are agents classified in the BNF as “not NHS” or “Drugs of Low Clinical Value”, or they are products on NICE’s “do not do” list or NHS England’s “should not routinely prescribe” list. |
|
Self Care
Not for routine prescribed in primary or secondary care unless as part of care for a long term condition. Instead, patients should be encouraged to self care with support from community pharmacy. |
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications |
|
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry. |
|
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. |
|
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist. |
|
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only |
|
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information. |
|
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use. |
|
|
|
